WO1989009627A1 - Catheter intravasculaire non-trombogenique recouvert de polymixine - Google Patents

Catheter intravasculaire non-trombogenique recouvert de polymixine Download PDF

Info

Publication number
WO1989009627A1
WO1989009627A1 PCT/US1989/001320 US8901320W WO8909627A1 WO 1989009627 A1 WO1989009627 A1 WO 1989009627A1 US 8901320 W US8901320 W US 8901320W WO 8909627 A1 WO8909627 A1 WO 8909627A1
Authority
WO
WIPO (PCT)
Prior art keywords
polymyxin
antibiotic
catheter
coating
patient
Prior art date
Application number
PCT/US1989/001320
Other languages
English (en)
Inventor
Edward Shanbrom
Original Assignee
Edward Shanbrom
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edward Shanbrom filed Critical Edward Shanbrom
Publication of WO1989009627A1 publication Critical patent/WO1989009627A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/06—Use of macromolecular materials
    • A61L33/12—Polypeptides, proteins or derivatives thereof, e.g. degradation products thereof
    • A61L33/128—Other specific proteins or polypeptides not covered by A61L33/122 - A61L33/126
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08—Materials for coatings
    • A61L29/085—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406—Antibiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents

Definitions

  • Blood compatibility is much more complex than the compatibility of a bio aterial with other body fluids or tissues.
  • the extent of the compatibility of blood with a specific biomaterial depends on whether the blood is moving (as in a heart device or blood vessel) or static (as in a storage bag or bottle) ; whether the blood is arterial or venous; flow patterns and especially changes in flow patterns; and interactions with red cells, white cells, platelets, plasma proteins and other blood components.
  • Blood is a heterogeneous, non-Newtonian fluid consisting of about 45% solids (red cells, white cells, platelets) and 55% plasma.
  • the plasma contains a variety of inorganic ions and a series of soluble proteins which can be classified as albumins, fibrinogenc, and globulins.
  • Blood compatibility of certain hydrophobic polymers, such as polydimethylsiloxane and the polyether polyuretha ⁇ » e ureas (PEUU) is inversely related to the wettability of the polymers. But certain hydrophilic polymers, :;uch as hydrogels, are also blood compatible. Certain i no er-type polymers and electrets (charged polymers) are also compatible with blood.
  • Blood compatibility is, to some extent, related to the nature of the prrteins that adsorb on the biomaterial surface. Whenever the blood contacts a foreign surface various plasma proteins adsorb on this surface. With some classes of polymers, such as hydrophobic polyether polyurethane ureas and the hydrophilic hydrogels, surfaces that adsorb mostly cold insoluble globulins, (fibronectin) and fibrinogen tend to be more thrombogenic than those that adsorb albumin. Protein adsorption is a slow process, requiring many hours or days, whereas thrombus formation begins in a matter of minutes.
  • biomaterials show initial thromboresistance but develop clots after several weeks, possibly because of changes in the adsorbed protein layer. While various theories seem adequate to explain why one polymer in a given class is more or less blood compatible than another polymer of the same class, no theory is adequate to explain all the variations in blood compatibility for natural and synthetic materials.
  • a number of biomaterials have limited utility in various extracorporal devices if a suitable anticoagulant, such as heparin, is added to the blood. However, administration of heparin reduces or prevents the . natural clotting of the blood.
  • Heparin a naturally occurring polyanionic mucopolysaccharide with a molecular weight of 12,000-16,000 has been attached to various surfaces by a variety of techniques.
  • heparin Although ionically bound heparin confers a significant degree of thromboresistance to the surface, the heparin desorbs and/or is inactivated with time and the basic thrombogenic nature of the surface prevails. Covalently bonded heparin maintains its thromboresistance longer, although the heparin is usually somewhat less active than the natural material. It appears likely that many experimental nonthrombogenic amido-amine polymers are thromboresistant because heparin is adsorbed at the amido-amin-s sites since many of the heparinization techniques involve a quaternary ammonium compound and heparin do ⁇ s form complexes with amino groups. Several experimental polymer systems have shown promise.
  • hydrogels include ths Ioplex materials and other hydrogels such as those based on 2-hydroxyethyl methacrylate or acrylamide. These materials may contain 50-80% water and it was claimed formerly that this was the basis of thromboresistance of hydrogels. More recent studies have shown that blood compatibility does not depend on the water content of hydrogels. Hydrogels normally lack physical or mechanical strength, a problem that has been partially solved by grafting hydrogels onto other substrates or by making a composite material with the hydrogel surface contacting the blood. Various lysing agents, such as urokinase or streptokinase, have been bonded to polymers with the intention of lysing any clotted material that might form on the surface.
  • lysing agents such as urokinase or streptokinase
  • PEUU polyether polyurethane ureas
  • the PEUU system can be mac'e with a wide variety of alkyl and/or aryl polymer groups and is often referred to as a segmented polyurethane.
  • Devices made from these hydrophobic polymers often show no evidence of thrombus build up on the surface, but emboli are noted in other parts of the test animal's body.
  • the principal feature and object of this invention is to provide an improved catheter which significantly reduces the risk of infection and, at the same time, reduces the risk of thrombus and embolus formation. Born into an environment laden with microbes, the body of man becomes infected from the moment of birth.
  • a typical skin bacterial flora will include 5 t aphyl ococci , Streptococci viridans, Streptococci faecalis, Corynebacteri a , and Mycobacteri a , and may, depending upon which skin area is examined, include Pneumococci , Cl ostridi a , Enteric bacilli, spi rochetes , Mycopl as mas . Streptococci anaerobic , as well as other species. Fungi such as the yeasts, Candida, C. albicans especially, is frequently a constituent of skin or membrane flora.
  • Staphyloco ,ci are spherical, gram- positive crganisms which cause a wide variety of suppurativ? diseases in man. Because staphylococci frequently become drug-resistant, they have risen to a position of special significance in clinical medicine.
  • the organism is destroyed without triggering the mutation-protection mechanism which is inherent in some bacteria.
  • the prior art includes many needles, catheters and other devices for insertion into the body.
  • the present invention is suitable for use with and may comprise as a element or as elements thereof such devices.
  • the assembly of breakaway needle and catheter is disclosed by , Luther et al in US patent 4702735, who also disclose the assembly of stylet and catheter, Luther, US patents 4668221 and 4610671, the assembly of stylet and catheter, Luther, US patent 4610671, the assembly with septum fitting for connecting adaptor and fluid tube, Luther et al, US patent 4559043, a small gauge, prn-split cannula and process for manufacture, Luther e l, US patent 4449973, apparatus for advancing oversized catheter through cannula, and the like, Luther, UJ patent 4401433, and cannula needle for catheter.
  • Trey et al, US patent 4377165 the assembly of breakaway needle and catheter.
  • Pepti e antibiotics produced by Bacillus species include several that are chemically closely related although produced by taxonomically different species: bacitracin from Baci l l us l ichen i formis and Baci l l us sub t i i i s and polymyxins from Bac i 1 1 us po lymyxa , Bac i l l us aerosporus , Bacillus colistinus , and Bacillus circulans.
  • the subclass of antibiotics of principal, but not exclusive, interest in this invention are the Polymyxins.
  • Polymyxins are antibiotics with a detergent like action, containing basic groups of the amino acid ⁇ ,7-diaminobutyrate plus a fatty acid side chain, which destroys the integrity of the membranes of gram-negative but commonly thought not to have such effect on gram-positive bacteria. Because of their n ⁇ uro- and nephrotoxicity the use of polymyxins is limited to serious infections caused by susceptible organisms which have built up resistance to or have natural resistance to other biocidal materials. Polymyxins are, for example, among . the few drugs effective against Pseudo onas aeruginosa which is a frequent and persistent secondary invader in patients under prolonged chemotherapy. The polymyxins inhibit the growth of a number of .
  • gram-negative organisms including Pseudomonas , Escheri chi a , K1 ebsi el 1 a , Enterobacter , Salmonel 1 a , Shigella, and Haemophi 1 us species, and are not inhibitors of growth of Proteus and gram-positive bacteria.
  • Preparations of sulfates of polymyxin B and of colistin (polymyxin E) are used for local, topical, oral, and intravenous medication, and the sodium N-sulfomethyl derivatives are used for intramuscular and intrathecal administration.
  • a wide range of mixed antibiotic formulations is marketed.
  • Example include the antibiotic class identified as colistin from a microorganism initially identified as a strain of Ba c i l l us co l is t inus and now classified Bac i l l us po lymyxa var. garyph a l us and a strain of B . po lymyxa from a soil sample taken in Moscow yielded an antibiotic which was designated as polymyxin M.
  • Bac i l l us b revis produces an antibiotic mixture of which tyrothricin is a major constituent. . J . B i o l . Chem .
  • Tyrothricin has been separated into three quite well known cationic cyclic polypeptide antibiotics, Tyrocidine A, B, and C.
  • Other cationic cyclic polypeptide antibiotics which are presently considered equivalent include the gramicidins, viomycins, capreomycins.
  • polymyxin as used here will, unless specified differently, means the general family of polymyxins and the equivalent, related cationic cyclic polypeptide antibiotic.'., the specific species Polymyxin B being the preferred compound.
  • All cf the polymyxins are basic polypeptides whose basicities are.associated with the uncommon basic amino acid, ⁇ ,7-diaminobutyric acid. They form water-soluble salts wit! mineral acids with only the phosphates being isolated in crystalline form.
  • the normal form of pharmaceutical presentation of the sulfates and the hydrochlorides is amorphous solids.
  • the water insolubility of the naphthalene-2-sulfonates and azobenzene-4-sulfonates is of advantage in purification of the polymyxins and crystalline forms can be obtained from aqueous alcohols.
  • Polar Yellow and other acid dyestuff salts, lcng-chain alkyl sulfates, etc, are very insoluble in water and are useful in the various purification procedures.
  • Intramuscular injection of polymyxins is painful and tends to result in an inflammatory reaction at the site of injection.
  • polymyxins When polymyxins are treated with formaldehyde and sodium birulfite they are converted into their sodium N-sulfomet'iyl derivatives, which are relatively free from causi n g pain upon injection and still retain most of their antibacterial activities.
  • the potency of these derivatives depends on regeneration in vivo to the parent compound so the nephrotoxicity is not significantly reduced.
  • the degree of N-sulfomethylation varies: mc.-st preparations of Coli-Mycin have about 50% of the maximum 7 sulfomethyl groups.
  • Polymyxins A and D each contain two D-amino acid residues, *rt ⁇ ile polymyxins B and E have one. This difference may be responsible for the higher nephrotoxicity with the A and D compounds.
  • the higher proportions of hydroxyamino acids found in A and D are reflected in the water solubility of the bases of these polymyxins, in contrast with that of polymyxins B and E and circulin A, which precipitate when aqueous solutions are neutralized.
  • Tyrocidine A, Tyrocidine B and Tyrocidine C are closely related polypeptides which are known to possess antimicrobial action comparable to that of the better known Polymyxin B.
  • Polymyxin B in isotonic saline (0.5%) is used intrathecally and sterile, pyrogen-free polymyxin B sulfate is available for intravenous infusion in cases of sever p . systemic infection (usually requiring hospitalization) .
  • the acute intravenous toxicity is reduced by sulfomethylation with formaldehyde and sodium metabisulfite, this toxicity is of little therapeutic importance because the polymyxin B sulfates have a satisfactory therapeutic index.
  • the main advantage of the sulfomethyl derivatives is the reduction cf pain at the site of intramuscular injection and thus making parenteral therapy tolerable to the patient.
  • An endotoxin detoxifying process which includes contacting * blood with fibrous carrier having Polymyxin fixed thereon is disclosed by Hanazawa Kazuyoshi, et al, US patent no. 4661260. he endotoxin detoxifying material comprising a " fibrous carrier to which Polymyxin is fixed. A r3thod of removing endotoxin .from> a fluid by contacting the fluid with the endotoxin detoxifying material comprising a carrier to which Polymyxin is fixed is also disclosed.
  • an object of this invention to provide a catheter which not only reduces the frequency and seriousness: of thrombus or embolus formation but also greatly reduces the risk of infection at the site of the invasion of the body by the catheter and in the vascular • system.
  • the present invention is embodied in an intravascular device the surface of which is coated with a cationic cyclic polypeptide antibiotics, of which the polymyxins are the best presently known examples, to render the surface non-thrombogenic.
  • the principle of the invention is applicable to any device which is designed or intended to reside in contact with blood for a period of time which would, without special precaution, result in the formation of thrombus on the surface, • hich may either attach to the surface or slough off as emboli.
  • Invasive devices for dwelling in contact with fibrinogen-fibrin containing fluid of a patient which contains fibrinogen-fibrin capable of forming clots generally are within the contemplated applications of the presei.l process and invention.
  • Such devices would include, for example, tubes introducing medication into or draining fluid from hydrencephaloceles and cavities in connection with the treatment of pleurisy and peritonitus and other diseases and infections, and in similar applications where it is important to avoid fibrin deposition and clotting are included within the devices referred to herein.
  • the principal applications being, of course, vascular devices such as catheters.
  • the invention is embodied in an intravascular catheter comprising a cannula constructed and dimensioned for insertion into an vascular system of a patient which is coated so as to be non-thrombogenic with a coating of cationic cyclic polypeptide antibiotic?., of which the polymyxins are the best presently known examples.
  • the catheter includes or comprises a cannula th* ⁇ inner and outer walls of which are coated with the rationic cyclic polypeptide antibiotic. If a non-cannulated catheter is used, then the coating is on the outsid ⁇ of the catheter.
  • a cationic cyclic polypeptide antibiotic e.g. the polymyxins, Polymyxin B is used in what is presently considered the best mode of carrying out the invention.
  • the cationic cyclic polypeptide antibiotic is coated onto the "surface(s) of the device which come into contact wiLh the blood.
  • the principal limitation upon the application of the present invention to all vascular devices is that the surfa-e of the device must be capable of being coated with the cationic cyclic polypeptide antibiotic and retaining the coating on the surface for a significant period of time.
  • Virtually any polymeric surface can be coated or can be treated to accept a coating of the cationic cyclic polypeptide antibiotic in sufficient amounts and with sufficient retention time to make the surface non- thrombogenic.
  • the advantageous and unexpected features of this invention include the discovery that providing a level of cationic cyclic polypeptide antibiotics, of which the polymyxins are the best presently known examples, in or on the surface of a catheter not only inhibits the growth of pathogenic gram negative bacteria, but also inhibits the growth of gram positive bacteria, inhibits the replicrtion of virus, inhibits the growth of fungal infection sites, prevents the development of tolerance to the antibiotic, and creates a non-thrombogenic surface on the catheter.
  • the intravascular, device e.g. a catheter is constructed and dimensioned for insertion into an vascular system of a patient and coated with the cationic cyclic polypeptide antibiotic by dipping, spraying cr other application techniques.
  • Cationic cyclic polypeptide antibiotics of which the polymyxins are the best presently known examples, may be used.
  • Polymyxin B is used here to exemplify the invention.
  • Teflon ® polytetrafluoro- ethylene .'..urfaces did not retain sufficient cationic cyclic polypeptide antibiotic to be non-thrombogenic when dipped into an aqueous solution at room temperature; however, when dipped in an aqueous solution of cationic cyclic polypeptide antibiotic, Polymyxin B, at 80°C. for half an hour, the surface became antimicrobial and non-thrombogenic.
  • the time- temperaturo relationships have not been fully developed but it is known that dipping the Teflon ® into aqueous cationic cyclic polypeptide antibiotic solutions of from about 70°C.
  • the polymer surface may be pre-treated with a softening or swelling solvent.
  • the acrylic acid and acrylate based polymers may be pre-treated with acetone or another ketone, dipped in the cationic cyclic polypeptide antibiotic solution, and then dried, in vacua if necessary, to remove all solvent.
  • Olefin based polymers may be swelled w:'.th many non-polar solvents and nearly all polymers ⁇ .re softened or swelled in some of the very strong solvents such as methylene chloride or dimethyl sulfoxide.
  • the antibiotics useful in this invention have more than adequate solubility in polar solvents generally to prepare solutions for carrying out the present invention.
  • Great care must be taken, of course, to assure complete removal of any solvent which is not fully compatible with the tissue and blood of the patient; thus, no particular solvent system is critical to the invention and suitable solvents can be selected based upon the data on polymer solubility, softening and swelling in many handbooks.
  • the surface be subjected to electron bombardment or other high energy radiation to break some of the surface bonds of the polymer and produce active sites to which the cationic cyclic polypeptide antibiotic may attach.
  • the cationic cyclic polypeptide antibiotics being very strong Lewis bases are commonly prepared and handled as salts.
  • the basic form directly, or converting the salt to the basic form the cationic cyclic polypeptide antibiotics become quite reactive and can be made to attach to naturally occurring or induced active sites on the polymer, as well as to dissolve into the polymer or form a physico- chemical b nd on the surface of the polymer.
  • Cationic cyclic polypeptide antibiotic e.g polymyxin
  • a coating in amount which is determined empirically to be effective to substantially prevent the growth of polymyxin- sensitive microorganisms and to inhibit thrombus formation on the catheter. The precise parameters as to the amount, of the antibiotic necessary to achieve this result have not been determined, nor are these parameters critical.
  • nonthrombogenic surface effects resulting from the use of the cationic cyclic polypeptide antibiotics, of which the polymyxins are the best presently known examples, of this invention may be enhanced by the additional use of known anticoagulants such as heparin and chelating .agents for calcium and magnesium, e.g. EDTA and citric acid.
  • known anticoagulants such as heparin and chelating .agents for calcium and magnesium, e.g. EDTA and citric acid.
  • a typical manufacturing process includes the steps.
  • the polymer may contain or be modified to include moieties or sites which can accept an electron pair and brought into contact with free (non-salt) polymyxin, which is _:asic, which will form a covalent bond with such moieties or sites.
  • anticoagulants e.g. heparin
  • various chelating and other agents may also be included i the solution or added separately.
  • Other specific antimicrobials may, for example, be included in the polymer, as is known in the prior art. Indeed, virtually any constituent which does not interfere with the described action of the cationic cyclic polypeptide antibiotics, of which the polymyxins are the best presently known examples, may be included in the polymer.
  • the invention is described as a vascular J rvasive device of any kind which is used in contact with blood having a coating on the polymer containing an antimicrobial anticoagulant consisting essentially of cationic cyclic polypeptide antibiotics, of which t e polymyxins are the best presently known examples.
  • the preferred form of the invention includes the polymyxin B, or other cationic cyclic polypeptide antibiotics, of which the polymyxins are the best presently known.
  • Catheters prepared as described herein were compared with -the same type of catheter which differed only in t ⁇ * e absence of the cationic cyclic, polypeptide antibiotic treated surface. Both catheters were dipped in whole b ood for various periods of time. In one such test, the catheters were compared for clotting after one hour in t ⁇ blood.
  • the catheters treated according to this invention were virtually free of blood on the outside, and were free-flowing and free of clots on the inside.
  • An identical catheter, absent the cationic cyclic polypeptide, when removed from the blood was coated on the outside and plugged substantially or entirely on the inside.
  • a representative sample of commercially available catheters were used as controls. In all instances, they were coated with blood clots and were fully or partially block inside the lumen.
  • polymyxin B coated catheters of this invention were very substantially less thrombogenic than identical catheters without thn polymyxin B constituent.
  • the catheters when removed, are generally quite clean and free of the large clots and coating of blood whici are normally found.
  • the small amount of blood which remains coupled with the antimicrobial action of the coating reduces the risk of infection to medical works, e.g. nurses, doctors and technicians, the most serio's of which is the risk of infection with the HIV (AIDS) virus.
  • the catheters of this invention exhibit a number of surprising and unpredictable characteristics, and accomplish results not previously accomplished, which Illustration.tly reduce the risks in using intravascular catheters.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Cathéter intravasculaire comprenant une canule conçue et dimensionnée de manière à s'insérer dans le système vasculaire d'un patient et revêtement de polymixine sur les surfaces de ladite canule en quantité suffisante pour prévenir substantiellement la croissance de micro-organismes réagissant à la polymixine et pour empêcher la formation de thrombus sur ledit cathéter.
PCT/US1989/001320 1988-04-07 1989-03-30 Catheter intravasculaire non-trombogenique recouvert de polymixine WO1989009627A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US178,988 1980-08-18
US17898888A 1988-04-07 1988-04-07

Publications (1)

Publication Number Publication Date
WO1989009627A1 true WO1989009627A1 (fr) 1989-10-19

Family

ID=22654759

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/001320 WO1989009627A1 (fr) 1988-04-07 1989-03-30 Catheter intravasculaire non-trombogenique recouvert de polymixine

Country Status (2)

Country Link
AU (1) AU3367489A (fr)
WO (1) WO1989009627A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590348A1 (fr) * 1992-09-26 1994-04-06 GRUPPO LEPETIT S.p.A. Cathéters centrals veineux chargés avec des antibiotiques lipodalbaheptide pour prévenir des infections liées aux cathéters

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1252377A (fr) * 1968-12-13 1971-11-03
US3896813A (en) * 1967-06-23 1975-07-29 Sutures Inc Sutures having long-lasting biocidal properties
EP0065884A1 (fr) * 1981-05-27 1982-12-01 Unitika Ltd. Cathéter urétral destiné à éviter l'infection de l'urètre et procédé pour le produire
WO1987007531A1 (fr) * 1986-06-13 1987-12-17 Royal Postgraduate Medical School Elimination d'endotoxines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896813A (en) * 1967-06-23 1975-07-29 Sutures Inc Sutures having long-lasting biocidal properties
GB1252377A (fr) * 1968-12-13 1971-11-03
EP0065884A1 (fr) * 1981-05-27 1982-12-01 Unitika Ltd. Cathéter urétral destiné à éviter l'infection de l'urètre et procédé pour le produire
WO1987007531A1 (fr) * 1986-06-13 1987-12-17 Royal Postgraduate Medical School Elimination d'endotoxines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Volume 82, No. 25, 23 June 1975, (Columbus, Ohio, US), ONISHI, REIKO, "Polymyxin B. II. Antiheparin Effect of Polymyxin B", page 33, Abstract 164902q; & SHIKOKU IGAKU ZASSHI, 1974, 30(6), 379-95. *
DIALOG INFORMATION SERVICES, File 155, Medline 81062598, Dialog Accession No. 04234598, KLINGEMAN H.G. et al., "Effects of Polymyxin B and E (Coli-Stin) on Blood Coagulation, Thrombooyte Function and Fibrin Structure"; & ARZNEIMITTELFORSCHUNG, 1980, 30(10), p 1719-21. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590348A1 (fr) * 1992-09-26 1994-04-06 GRUPPO LEPETIT S.p.A. Cathéters centrals veineux chargés avec des antibiotiques lipodalbaheptide pour prévenir des infections liées aux cathéters

Also Published As

Publication number Publication date
AU3367489A (en) 1989-11-03

Similar Documents

Publication Publication Date Title
US4950256A (en) Non-thrombogenic intravascular time release catheter
AU611030B2 (en) Non-thrombogenic intravascular time release catheter
EP0781566B1 (fr) Mucopolysaccharide soluble dans des solvants organiques, composition et matériaux antibactériens et antithrombogéniques
JP6962901B2 (ja) 物理的操作または殺菌の後に大きな生物活性を有する固定化された生物活性物質
US5578598A (en) Polyelectrolyte complex antibacterial agent in antibacterial material
US5997815A (en) Article with antimicrobial coating
EP0051354B1 (fr) Articles antithrombogéniques
US8986713B2 (en) Medical device capable of being compacted and expanded having anti-thrombin III binding activity
CN112587734A (zh) 一种基于仿生多巴胺的多功能涂层及其制备方法和应用
US20100272775A1 (en) Immobilized biologically active entities having a high degree of biological activity following sterilization
CA2087102C (fr) Composition anti-thrombogene et(ou) anti-microbienne
CN109789244B (zh) 多肽和透明质酸涂层
US20030161938A1 (en) Composition and method for coating medical devices
SwART et al. Require the Presence of Infection
WO1989009627A1 (fr) Catheter intravasculaire non-trombogenique recouvert de polymixine
Lamba et al. The influence of thrombus components in mediating bacterial adhesion to biomaterials
JP2010047764A (ja) 生体適合性ポリマー
EP2540325B1 (fr) Revêtement antimicrobien à base de peptides
JP4110430B2 (ja) 抗菌性付与抗血栓性材料
JP3690550B2 (ja) 抗菌性付与抗血栓性材料
EP0853947A1 (fr) Matériel matriciel contenant plusieurs matériaux bio-actifs
RU2388495C1 (ru) Способ получения тромборезистентных полимерных материалов
WO2004058324A2 (fr) Methodes et dispositifs d'acces veineux antithrombotiques
IE911473A1 (en) Anti-thrombogenic and/or anti-microbial composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE